Health FDA Endorses Zepbound for Sleep Apnea SufferersBy Dave Antrobus20 December 2024 The US Food and Drug Administration has given its nod to Zepbound, a weight-loss drug now approved for obstructive sleep…
Health Evaluating Novo Nordisk’s CagriSema in the Weight-Loss Race Against Lilly’s ZepboundBy Sam Allcock20 December 2024 Novo Nordisk has introduced its combination drug, CagriSema, in a recent major trial to challenge Eli Lilly’s Zepbound. This long-standing…
Health FDA Confirms Resolution of Eli Lilly’s Drug Shortage CrisisBy Dave Antrobus19 December 2024 The FDA has announced that the shortage of Eli Lilly’s major weight-loss and diabetes medications is resolved. This news marks…
Health Zepbound Outperforms Wegovy in Weight Loss Study, Eli Lilly ReportsBy Sam Allcock4 December 2024 Eli Lilly’s new clinical trial data highlights a significant breakthrough. Adults taking Zepbound, the brand name for tirzepatide, lost nearly…
Business International Summit Spurs £63 Billion Investment and Creates 38,000 UK JobsBy Sam Allcock15 October 2024 The International Investment Summit has catalysed a monumental financial influx into the United Kingdom, securing £63 billion and heralding the…
Tech & Gadgets Eli Lilly backs NanoSyrinx in £10m funding ventureBy Scott Dylan10 September 2024 NanoSyrinx, a biotech innovator from Coventry, secures £10m funding.Major investors include US giant Eli Lilly and British Growth Fund.Funds to…
Business UK Planning Laws Hinder Investment, Warns Eli Lilly CEOBy Scott Dylan1 July 2024 Dave Ricks, CEO of Eli Lilly, has raised concerns over the UK’s current planning procedures. These regulations reportedly impede rapid…
